In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.005(1.79%) |
Mkt cap ! $117.3M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.5¢ | $180.4K | 631.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 70379 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 69706 | 7 |
View Market Depth
| Last trade - 13.34pm 18/09/2025 (20 minute delay) ? |
| PAR (ASX) Chart |